OmniAb Q3 revenue falls 20% to $5.5M; net loss widens to $15.7M

OmniAb, Inc.

2023-Q3 EPS reported -$0.37 revenue$29,342,000

Q3 2023 revenue $5.5M (down 20% YoY); net loss $15.7M ($0.16/share) vs $12.6M loss in Q3 2022.
Active partner programs 314, up from 291 at year-start; added Novartis, GigaMune, Polaris as new partners.
Cash & short-term investments $96.6M at Sep 30; expects year-end cash slightly below year-end 2022.
Nine-month revenue $29.3M (up 24% YoY) from milestone payments; net loss $36.6M ($0.37/share).
Appointed Steve Love to Board (Audit Chair) and Yasmina Abdiche as VP of Exploratory Research.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

OmniAb, Inc. reported three and nine months ended September 30, 2023 results: revenue $5.5 million, net income $15.7 million, or $0.16 per share.

Period: three and nine months ended September 30, 2023
Revenue: $5.5 million
Net income: $15.7 million, or $0.16 per share
Result: reported results

Exact text from the filing

Virtual Event later today, which will include an overview of our new Omni dAb TM technology.” Third Quarter 2023 Financial Results Revenue for the third quarter of 2023 was $5.5 million, compared with $6.9 million for the same period in 2022, with the decrease primarily driven by lower service revenue as a result of the completion of discovery work on certain

View on SEC.gov

Browse all earnings releases →

OmniAb, Inc. filing history →

Source: SEC EDGAR

accession 0001846253-23-000117

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.